Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock

BRISBANE, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera Therapeutics”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced the pricing of an underwritten public offering of 6,138,108 shares of its Class A common stock at a price to the public of $42.50 per share.

GlobeNewsWire • Dec 10, 2025

Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock

BRISBANE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera Therapeutics”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced its plans to commence a public offering, subject to market and other conditions, to issue and sell $200.0 million of shares of its Class A common stock.

GlobeNewsWire • Dec 8, 2025

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on December 2, 2025, the Compensation Committee of the Board of Directors of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 42,000 shares of Class A common stock and restricted stock units (RSUs) underlying 21,000 shares of Class A common stock to seven (7) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan).

GlobeNewsWire • Dec 5, 2025

Vera Therapeutics, Inc. (VERA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Vera Therapeutics, Inc. (VERA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Seeking Alpha • Dec 3, 2025

Why Vera Therapeutics Stock Rocked the Market on Tuesday

The biotech received a significant boost from a new analyst note. The prognosticator authoring it reiterated his strong buy recommendation on the stock.

The Motley Fool • Dec 3, 2025

Why Vera Therapeutics Stock Crushed it Today

An analyst expressed his very bullish view on the biotech in a new research note. He reiterated his equivalent of a buy recommendation, and his lofty price target.

The Motley Fool • Nov 27, 2025

Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors

BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of James R.

GlobeNewsWire • Nov 26, 2025

Vera Therapeutics to Participate at Upcoming Investor Conferences

BRISBANE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will present and participate in one-on-one meetings at upcoming investor conferences.

GlobeNewsWire • Nov 24, 2025

Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit

BRISBANE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will present at the TD Cowen Immunology & Inflammation Summit, which is taking place virtually from November 12-13, 2025.

GlobeNewsWire • Nov 10, 2025

Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy

Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgAN ORIGIN Phase 3 trial met its primary endpoint at the prespecified interim analysis of proteinuria reduction with 46% reduction from baseline and 42% reduction vs placebo at week 36 (p

GlobeNewsWire • Nov 7, 2025